FDA accepts sNDA for review of Myfembree in uterine fibroid treatment

June 13, 2022

The FDA recently announced the acceptance of a supplemental New Drug Application for relugolix 40 mg, estradiol 1 mg, and norethindrone acetate .5 mg in the treatment of heavy menstrual bleeding associated with uterine fibroids in premenopausal women.

The latest in contraceptives for 2022

May 09, 2022

A presentation at the 2022 American College of Obstetricians and Gynecologists’ Annual Clinical & Scientific Meeting discussed the recent updates in contraceptives including new nonhormonal intrauterine devices.